Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.
Eight different batches of intravenous immunoglobulin from 3 different manufacturers were tested for neutralizing activities against all currently known streptococcal superantigens. Statistically significant variation among different intravenous immunoglobulin preparations (P<.0001) and between individual streptococcal superantigens (P<.0001) was observed. These results might be helpful for optimizing the type and dose of intravenous immunoglobulin used in adjunctive therapy for severe invasive streptococcal disease.
Schrage
Birgit
B
Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. t.proft@auckland.ac.nz.
Duan
Guowen
G
Yang
Lily P
LP
Fraser
John D
JD
Proft
Thomas
T
D000942:Antigens, Bacterial / Q000276:immunology*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000592:standards* / Q000627:therapeutic use; D009500:Neutralization Tests; D012772:Shock, Septic / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*; D013291:Streptococcus / Q000276:immunology*; D018089:Superantigens / Q000276:immunology*
D000942:Antigens, Bacterial; D016756:Immunoglobulins, Intravenous; D018089:Superantigens